nifekalant
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
The present study was conducted to clarify multiple cardiohemodynamic and electrophysiological properties including inotropic…
J-wave syndrome is one of the causes for idiopathic ventricular fibrillation (VF), characterized by early repolarization at the…
We report a case of intraoperative cardiac arrest in a patient with mitochodorial encephalomyopathy undergoing pulmonary wedge…
BACKGROUND
Anesthesia sometimes suppresses ventricular tachyarrhythmias (VT) resistant to conventional pharmacological treatment…
BACKGROUND
Spiral re-entry plays the principal role in the genesis of ventricular tachycardia and ventricular fibrillation (VT/VF…
BACKGROUND
Nifekalant, a class III anti-arrhythmic agent, has been used clinically at serum concentrations of 1-10 micromol/L in…
There have been extensive efforts to develop I(Kr) channel blockers as a new antiarrhythmic agent for atrial or ventricular…
The proarrhythmic effects of class III antiarrhythmic agents and non-cardiovascular drugs, which have been shown to prolong QT…
Pure class III antiarrhythmic agents cause reverse use-dependent QT prolongation. Nifekalant is a new class III antiarrhythmic…
INTRODUCTION Most sudden cardiac death is primarily the result of lethal ventricular arrhythmias. The Cardiac Arrhythmia…